Source - GNW

Summit Therapeutics plc

("Summit" or the "Company")

SUMMIT THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30 APRIL 2017 ON 14 JUNE 2017

Oxford, UK, 13 June 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will announce its financial results for the first quarter ended 30 April 2017 on 14 June 2017.

About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit Therapeutics
Glyn Edwards / Richard Pye (UK office)

Erik Ostrowski / Michelle Avery (US office)

 
 

Tel: +44 (0)1235 443 951

  +1 617 225 4455
Cairn Financial Advisers LLP
(Nominated Adviser)

Liam Murray / Tony Rawlinson

 
 

 

Tel: +44 (0)20 7213 0880
N+1 Singer

(Broker)

Aubrey Powell / Lauren Kettle

 
 

 

Tel: +44 (0)20 7496 3000
MacDougall Biomedical Communications

(US media contact)

Karen Sharma

 

Tel: +1 781 235 3060
[email protected]
Consilium Strategic Communications
(Financial public relations, UK)

Mary-Jane Elliott / Sue Stuart /
Jessica Hodgson / Lindsey Neville

Tel: +44 (0)20 3709 5700

[email protected]


-END-




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Summit Therapeutics plc via Globenewswire